Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis
European Journal of Neurology · 2024-12 · 31 (12)
DOI: 10.1111/ene.16490 ↗At a glance
Randomisierte kontrollierte Studie in European Journal of Neurology, published online on 2024-10-07. Written by Ali A Habib and 8 co-authors. Institution: University of California, Irvine, California, USA. Major MEDLINE topics: Myasthenia Gravis, Receptors, Cholinergic, Antibodies, Monoclonal, Humanized. Cited 16 times so far (Crossref); 26 references. The full text is freely available (open access, CC BY 4.0). Funded by: Alexion, AstraZeneca Rare Disease, Alexion Pharmaceuticals.
Abstract (original language)
Background and Purpose The efficacy and safety of ravulizumab, a terminal complement C5 inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive (AChR Ab+) generalized myasthenia gravis (gMG) were demonstrated in the CHAMPION MG study (NCT03920293). This analysis aimed to characterize the latency to onset of a clinically meaningful therapeutic effect for ravulizumab.
Methods
Post hoc analysis of data collected for up to 60 weeks from CHAMPION MG was performed to assess the timing of response to ravulizumab. Response was analyzed based on reductions of ≥2 and ≥3 points (minimal clinically important differences [MCIDs]) in Myasthenia Gravis–Activities of Daily Living (MG‐ADL) and Quantitative Myasthenia Gravis (QMG) total scores, respectively, and on more rigorous reductions of ≥3 and ≥5 points, respectively. Time to first response was assessed using the Kaplan–Meier product‐limit method.
Results
The median (95% confidence interval) time to first response was 2.1 (2.1–2.6) and 4.1 (2.3–10.0) weeks for reductions of ≥2 and ≥3 points in MG‐ADL total score, respectively ( n = 139), and 4.1 (2.1–10.0) and 18.3 (11.0–33.4) weeks for reductions of ≥3 and ≥5 points in QMG total score, respectively ( n = 134). Cumulative response rates at Week 60 (data cut‐off) were 88% and 82% for ≥2‐ and ≥3‐point MG‐ADL score reductions, respectively, and 86% and 59% for ≥3‐ and ≥5‐point QMG score reductions, respectively.
Conclusions
The median times to MCID with ravulizumab treatment in patients with AChR Ab+ gMG were ~2 weeks and ~4 weeks based on MCID MG‐ADL and QMG total score reductions, respectively.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- University of California, Irvine, California, USA.
- Department of Neurology, University of Miami Miller School of Medicine, Miami, Florida, USA.
- Department of Neurology, University of South Florida Morsani College of Medicine, Tampa, Florida, USA.
- Department of Neurology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
- Reference Center for Neuromuscular Disorders and Amyotrophic Lateral Sclerosis, CHU La Timone, Aix-Marseille Université, Marseille, France.
- Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan.
ORCID profiles: Ali A Habib, Andreas Meisel, Masahisa Katsuno, James F Howard
Funding
- Alexion, AstraZeneca Rare Disease
- Alexion Pharmaceuticals
Cite
APA
Habib, A. A., Benatar, M., Vu, T., Meisel, A., Attarian, S., Katsuno, M., Liao, S., Beasley, K. N., & Howard, J. F. (2024). Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis. European Journal of Neurology, 31(12). https://doi.org/10.1111/ene.16490
Vancouver
Habib AA, Benatar M, Vu T, Meisel A, Attarian S, Katsuno M, et al. Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis. European Journal of Neurology. 2024;31(12). doi:10.1111/ene.16490
BibTeX
@article{Habib2024,
author = {Habib, Ali A and Benatar, Michael and Vu, Tuan and Meisel, Andreas and Attarian, Shahram and Katsuno, Masahisa and Liao, Serena and Beasley, Kathleen N and Howard, James F},
title = {Time to response with ravulizumab, a long‐acting terminal complement inhibitor, in adults with anti‐acetylcholine receptor antibody‐positive generalized myasthenia gravis},
journal = {European Journal of Neurology},
year = {2024},
volume = {31},
number = {12},
doi = {10.1111/ene.16490}
}
EUVIMED